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Background: We aimed to assess cancer incidence and mortality for all-causes and factors related to risk of death
in an Italian cohort of HIV infected unselected patients as compared to the general population.
Methods: We conducted a retrospective (1986–2012) cohort study on 16 268 HIV infected patients enrolled in the
MASTER cohort. The standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were computed
using cancer incidence rates of Italian Cancer Registries and official national data for overall mortality. The risk
factors for death from all causes were assessed using Poisson regression models.
Results: 1,195 cancer cases were diagnosed from 1986 to 2012: 700 AIDS-defining-cancers (ADCs) and 495
non-AIDS-defining-cancers (NADCs). ADC incidence was much higher than the Italian population (SIR = 30.8, 95%
confidence interval 27.9-34.0) whereas NADC incidence was similar to the general population (SIR = 0.9, 95% CI
0.8-1.1). The SMR for all causes was 11.6 (11.1-12.0) in the period, and it decreased over time, mainly after 1996, up
to 3.53 (2.5-4.8) in 2012. Male gender, year of enrolment before 1993, older age at enrolment, intravenous drug use,
low CD4 cell count, AIDS event, cancer occurrence and the absence of antiretroviral therapy were all associated
independently with risk of death.
Conclusions: In HIV infected patients, ADC but not NADC incidence rates were higher than the general population.
Although overall mortality in HIV infected subjects decreased over time, it is about three-fold higher than the
general population at present.
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The introduction and widespread use of combination
antiretroviral therapy (cART) in the mid-1990s has
dramatically improved the health status of HIV-infected
individuals, whose life expectancy is now similar to that
of the general population [1-7]. The progressive aging of
HIV-positive patients due to the decrease of AIDS-
related deaths has led to increasing occurrence of other
chronic disease, such as cancer [8-11], which is now the
leading cause of death among these patients [3-5].* Correspondence: e.raffetti@unibs.it
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unless otherwise stated.However, despite the improvement in overall survival,
total mortality still differs between HIV infected and
non-infected subjects [2,12].
Limited data are available on cancer incidence and
mortality in Italian HIV-infected subjects and most of
them were provided by a record linkage between national
AIDS registry and cancer registries performed at the
beginning of cART era [13-17].
In recent years, some international pooling-cohort stud-
ies have described cancer incidence and mortality after
diagnosis of cancer in HIV-infected subjects [4,5,11,18].
However, Italian HIV-infected patients show different
characteristics with respect to patients included in
European and US cohorts, particularly a higher likelihoodThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing, alcohol abuse and hepatitis B (HBV) and C (HCV)
co-infections [19]. Indeed, recently, the ART Cohort
Collaboration found substantial differences in mortality
rates between HIV subjects living in Europe and in North
America due to various factors, including behavioral char-
acteristics and co-morbidities such as HCV infection [20].
The aims of this study were: (i) to describe cancer inci-
dence and mortality from all causes in a large unselected
Italian cohort of HIV-infected patients from 1986 to 2012,
and (ii) to assess the factors associated with risk of death.
Methods
MASTER cohort and study population
The Italian MASTER cohort is a hospital-based multicen-
ter, open, dynamic cohort established in the mid-1990s,
with retrospective patients’ enrolment from 1986 to 1997
and prospective recruitment subsequently. At present, the
cohort includes about 24,500 HIV-infected adults, aged
18 years or older, in care at eight Italian hospitals [19]. For
this study, two centers were excluded because did not
codify cancer cases. Enrollment in MASTER is independ-
ent of the HIV disease stage, degree of immunosuppres-
sion or use of antiretroviral therapy. Clinical data are
recorded every three/four months in an electronic chart
(NetCare™ or Health&Notes™). Data merging and cleaning
are performed at a central level every six months.
In this study, we have conducted a retrospective cohort
study from January 1986 to September 2012 on HIV-
infected patients for which the following data were avail-
able: date of first HIV positive test or cohort-entry, date of
death for patients died during the study period, date of last
visit for patients still alive or lost to follow-up and at least
one CD4 cell count. Patients with cancer diagnosis before
enrolment in the cohort were excluded. Patients without
data recorded for one year and over were considered lost
to follow-up. We defined cART regimen the treatment
with 3 or more antiretroviral drugs belonging to at least
two different drug classes, and “sub-optimal cART” any
other regimen.
In this study we retrieved from the MASTER electronic
database: gender, age at enrolment, country of origin, HIV
exposure group, period of enrolment in the cohort and
Hepatitis C or B co-infection. Furthermore, values of
HIV-RNA, CD4 cell count, AIDS event and cART at
enrolment and every year were also collected.
Cancer diagnoses and deaths
Cancer diagnoses were collected from medical records
and verified through a standardized process, including
detailed record abstraction and checking. Only incident
cancers occurring during the follow-up were included,
whereas cancer recurrences and metastases were ex-
cluded. Cancer type and site were coded according to theInternational Classification of Diseases (ICD), 9th revision,
and the International Classification of Diseases, 10th revi-
sion [21]. Malignancies were defined as AIDS-defining-
cancers (ADCs), including non-Hodgkin’s lymphoma,
Kaposi’s sarcoma and invasive cervical carcinoma, and
non-AIDS-defining-cancers (NADCs), including all the
other types of cancers. Vital status and date of death were
ascertained through clinical charts, and through a record-
linkage with Local Health Authority mortality registers in
about one third of patients.Statistical analysis
Patients were classified into 3 groups according to cancer
occurrence: i) patients who developed ADC; ii) patients
who developed NADC; iii) patients without cancer diag-
nosis (free-cancer patients). Quantitative variables were
compared by the Mann–Whitney test; the χ2test was used
to assess independence between qualitative variables.
The follow-up was determined from the date of enroll-
ment in the cohort to the end of the observation period.
For computing cancer incidence, the end of the period was
established as: the date of cancer diagnosis, September
30th, 2012 (December 31th 2009 for SIR analysis),
death, or last follow-up visit for patients lost to follow-
up, whichever occurred first. For mortality analysis, the
observation period finished at the earliest of September
30th, 2012, death or last follow-up visit for patients lost
to follow-up. Cancer incidence rates (IRs) were com-
puted for ADC and NADC, separately, whereas mortal-
ity rates were calculated for three groups: patients with
ADC, NADC, or without cancer. Incidence and mortality
rates were computed for two periods according to cohort
entry year: before cART-era (before 1998, i.e. up to 1997)
and during the cART-era (in and after 1998). All the rates
were calculated dividing observed cases by the corre-
sponding person-years at risk, standardized for gender
and age using the direct method with the European popu-
lation as the standard and truncated at 65 years-old. The
rates were expressed per 1,000 person-years (1000 PYs).
Cancer incidence in this cohort was compared with that
observed in the Italian general population computing
the standardized incidence ratios (SIRs) and their cor-
responding 95% confidence intervals (95% CIs), with
the Byar’s approximation of Poisson model, using the
Italian general population gender- and age-specific
rates provided by Italian Cancer Registries. Since cancer
incidence rates vary substantially from one region to
another in Italy and the composition of HIV cohort is
highly unbalanced (15.6% from South Italy and 84.4%
from North Italy), 5 population cancer registries (Torino,
Varese, Ferrara, Latina, Ragusa) with data collected in
1986–2009 period were selected and weighted accord-
ing to area of residence of HIV subjects for a proper
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from cancer registries were updated to that year.
Similarly, the standardized mortality ratios (SMRs) for
all causes were computed as the ratio of observed to the
expected numbers of deaths, and their corresponding 95%
CIs were estimated using the Byar’s approximation of
Poisson model. For this purpose, we used the sex- and
age-standardized mortality rates of the Italian general
population in 1986–2003 and 2006–2011 provided by the
Istituto Superiore di Sanità. For convenience, we extended
the mortality rates in 2003 and 2006 to 2004 and 2005,
respectively, and the mortality rate in 2011 to 2012. Three
analyses of the SMRs were performed: i) the temporal trend
in 1986–2012; ii) the global SMRs, calculated for the overall
cohort and iii) SMRs stratified for gender and age. To
evaluate time trend of SMR, we fitted a regression model
with fractional polynomial terms for year as independent
variable, using the Akaike’s information criterion to choose
the number of degrees of fractional polynomial terms.
The association of each investigated variable with all-
cause mortality was tested by univariate and multivariate
analysis using time dependent Poisson regression models
with study period divided into intervals of 1-year dur-
ation, which provided estimates of relative risks (RRs),
their 95% CIs and p-values. Gender, age at enrolment,
intravenous drug use as risk factors, hepatitis C or B
virus co-infection and year of enrolment were included
in the model as fixed covariates. Cancer occurrence,
AIDS events (ADC was not considered as an AIDS
event), CD4 cell count and antiretroviral therapy were
included as time-dependent covariates.
Finally, to evaluate the causal effect of cART on risk of
death, we used a marginal structural statistical model
[22], with cancer occurrence, AIDS events, and CD4 cell
count as time-dependent covariates. Inverse-probability-
of-treatment weights were determined on the basis of
the propensity score estimated by multinomial logistic
regression with antiretroviral therapy as the dependent
variable, categorized as i) cART: (≥3 antiretroviral drugs
from at least 2 different classes), ii) sub-optimal-cART
(any other regimen) ,and iii) no therapy.
The selection of variables for the most parsimonious
models was performed using a backward stepwise pro-
cedure, with p = 0.20 for retaining each variable in the
models. However, age and gender were also retained in
all the models as possible confounders.
All statistical tests were two-sided, assumed a level of
significance of 0.05 and were performed using Stata 12
software (Stata Statistics/Data Analysis 12.0 - Stata
Corporation, College Station, TX, USA).
Ethics procedures
At first visit, patients provide written informed consent
for including their clinical and biological data in theMASTER database for scientific purpose. Data submitted
by the participating clinics to the data center are anon-
ymized. The study was approved by the Ethical Commit-
tees of the Hospital Spedali Civili of Brescia (Coordinating
Centre) and of the following Institutions: University
Hospital of Ferrara, Ferrara; AO Papa Giovanni XXIII,
Bergamo; University of Bari, Bari; San Gerardo de’ Tintori”
Hospital, Monza; Hospital of Cremona, Cremona; “Santa
Maria Annunziata” Hospital, Firenze; University of Sacred
Heart, Roma.Results
Cancer incidence
A total of 16,268 HIV infected patients were enrolled,
contributing 134,291 person-years (median 6.2 years of
follow-up). The cumulative probability of loss to follow-up
at 3 years after enrolment was 22.7% (95% CI 22.0%-23.3%).
A total of 1,195 cancer cases were diagnosed from 1986 to
2012 in 1,159 patients: 700 (60%) ADCs and 495 (40%)
NADCs, including 36 individuals with both ADC and
NADC. The patients’ characteristics at enrolment are
shown in Table 1. At baseline, patients with NADC, respect
to those with ADC and those without cancer, were older,
had a higher proportion of intravenous drugs users (IDUs),
HBV or HCV co-infection, and an intermediate CD4 cell
count mean.
At cancer diagnosis, patients with NADC were older
than those with ADC (median age of 45 [IQR 39–53] vs.
39 [IQR 33–46] years, p <0.001) and showed a higher
CD4 cell count (median of 334 [IQR 180–482] vs. 145
[IQR 46–329] cell/mm3, p <0.001) (data not shown in
Table).
The comparison of sex- and age-standardized incidence
rates (IRs) for all ADCs and for all NADCs from before to
after 1998 showed a significant decrease of the IRs for
ADC, from 14.7 (95% CI 9.8-19.5) to 4.2 (3.7-4.8) per
1000 PYs (p = 0.002), but an increase of the IRs for NADC
from 3.4 (0.5-6.3) to 4.6 (3.9-5.3) per 1000 PYs (p = 0.01).
Overall incidence of ADCs was higher than the Italian
general population with SIR = 30.8 (27.9-34.0), with a sig-
nificant decrease from 67.7 (59.3-77.1) to 30.8 (27.9-34.0),
before and after 1998, respectively. The global incidence
of NADCs was similar to that detected in the Italian gen-
eral population with SIR = 0.9 (0.8-1.1), both before and
after 1998, with SIR = 0.9 (0.6-1.2) and SIR = 0.9 (0.8-1.1),
respectively (data not shown in Table).
The SIRs of specific cancers in the whole period are
shown in Table 2. Very high SIRs were found, in de-
creasing order, for Kaposi’s sarcoma (SIR = 168.5), penis
(SIR = 28.0), non-Hodgkin lymphoma (SIR = 24.5), tongue
and lingual tonsil (SIR = 22.1), vagina and vulva (SIR = 22.1),
cervix (SIR = 17.9), liver (SIR = 10.6) and Hodgkin lymph-
oma (SIR = 11.8).
Table 1 Patients’ characteristics at enrolment according to cancer-categories
Variables Categories Total ADC NADC Without cancer P value
Total 16268 688 471 15109
Gender Male 12116 (74.5) 549 (79.8) 360 (76.4) 11207 (74.2) 0.003
Female 4152 (25.5) 139 (20.2) 111 (23.6) 3902 (25.8)
Age at enrolment (years) 18-34 9797 (60.2) 369 (53.6) 228 (48.4) 9200 (20.9) <0.001
35-44 4278 (26.3) 189 (27.5) 121 (25.7) 3968 (26.3)
45-54 1538 (9.5) 91 (13.2) 71 (15.1) 1376 (9.1)
55-64 513 (3.1) 36 (5.2) 41 (8.7) 436 (2.9)
>65 142 (0.9) 3 (0.4) 10 (2.1) 129 (1.0)
Mean (SD) 34.2 (9.8) 35.6 (10.3) 37.8 (11.9) 34.1 (9.7) <0.001
Year of enrolment 1986-1989 2275 (14.0) 79 (16.8) 135 (19.6) 2061 (13.6) <0.001
1990-1993 2835 (17.4) 99 (21.0) 121 (17.6) 2615 (17.3)
1994-1997 2465 (15.1) 98 (20.8) 137 (19.9) 2230 (14.8)
1998-2001 2522 (15.5) 73 (15.5) 101 (14.7) 2348 (15.5)
2002-2005 2539 (15.6) 70 (14.9) 108 (15.7) 2361 (15.6)
2006-2012 3632 (22.3) 52 (11.0) 86 (12.5) 3494 (23.1)
IDUs No 8374 (51.5) 363 (52.8) 200 (42.5) 7811 (51.7) <0.001
Yes 7894 (48.5) 325 (47.2) 271 (57.5) 7298 (48.3)
HBV/HCV co-infection No 8374 (51.5) 363 (52.8) 200 (42.5) 7811 (51.7) <0.001
Yes 7894 (48.5) 325 (47.2) 271 (57.5) 7298 (48.3)
CD4 cell count , cell/mm3 0-49 1151 (7.1) 95 (13.8) 28 (5.9) 1028 (6.8) <0.001
50-99 940 (5.8) 59 (8.6) 31 (6.6) 850 (5.6)
100-199 2038 (12.5) 136 (19.8) 70 (14.9) 1832 (12.1)
200-349 3464 (21.3) 144 (20.9) 100 (21.2) 3220 (21.3)
350-499 3346 (20.6) 110 (16.0) 107 (22.7) 3129 (20.7)
≥500 5329 (32.8) 144 (20.9) 135 (28.7) 5050 (33.4)
Mean (SD) 416.8 (298.6) 316.7 (272.6) 401.8 (300.8) 421.8 (298.9) <0.001
Log10 HIVRNA, copies/mL Mean (SD) 3.1 (1.4) 3.3 (1.5) 3.0 (1.4) 3.1 (1.4) NS
Treatment-naïve No 14179 (87.2) 610 (88.7) 412 (87.5) 13157 (87.1) NS
Yes 2089 (12.8) 78 (11.3) 59 (12.5) 1952 (12.9)
Patients with both ADC and NADC diagnosis (n = 36) were considered as ADC or NADC on the basis of which first occurred cancer.
Abbreviations: ADC AIDS-defining-cancer, NADC non-AIDS-defining-cancer, SD standard deviation, NS not statistically significant (p > 0.05), IDUs intravenous drug users,
HBV/HCV co-infection hepatitis B virus/hepatitis C virus positivity.
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A total of 2,847 (17%) patients died during follow-up
(2,191 patients before and 656 after 1998), with a mortality
rate of 19.3 per 1,000 PYs, from 57.3 to 13.3 per 1,000
PYs, before and after 1998, respectively. The sex- and age-
standardized mortality rates showed a 2–3 fold decline in
both patients without cancer and those with ADC, but a
2-fold increase among individuals with NADC in the
period after, with respect to before 1998 (Table 3).
The HIV-infected patients had a higher mortality than
the Italian general population, showing a global SMR of
11.6 (11.1-12.0), higher in females than in males (16.0
[14.7-17.4] vs. 10.8 [10.4-11.3]) (data not shown in Table).
The SMR for all causes showed a steady decrease after
1996, up to 2006, and it was stable afterwards, thoughmortality was still higher than the general population in
2012, with SMR = 3.53 (2.5-4.8) (Figure 1a). The gender-
and age-stratified SMRs are shown in Figure 1b. The
SMRs decreased with increasing age, from 18.3 (14.3-23.2)
in those aged 20–24 years to 2.1 (1.5-2.9) in those aged
65–69 years, and 1.3 (0.8-1.2) in patients aged 70 years
or older (Figure 1b). Among patients of 20–39 years of
age, women showed higher SMRs than men, from 38.2
(24.2-57.3) and 14.6 (10.7-19.4) in subjects aged 20–24
to 28.1 (23.2-33.6) and 19.9 (18.2-21.8) in subjects aged
35–39, in females and males, respectively.
Predictors of mortality for all causes
We evaluated the factors associated with death from all
causes by univariate and multivariate analysis, including
Table 2 Observed and expected cancers among the HIV-infected patients as compared to the general population
Observational-time 1986-2009
Cancer type or site (ICD-10) Observed (n) Expected (n) SIR (95% CI)
AIDS-defining-cancer
Kaposi’s sarcoma (C46) 287 1.7 168.5 (149.6-189.2)
Cervix Uteri (C53)^ 41 2.3 17.9 (12.8-24.2)
Non-Hodgkin lymphoma (C82-5, C96) 313 12.8 24.5 (21.8-27.3)
Non-AIDS-defining-cancer
Tongue and lingual tonsil (C01-C02) 5 0.2 22.1 (7.1-51.5)
Stomach (C16) 9 6.5 1.4 (0.6-2.6)
Colon (C18) 32 14.2 2.2 (1.5-3.2)
Rectum-Anus (C19-21) 24 7.7 3.1 (2.0-4.7)
Liver, primary (C22) 61 5.8 10.6 (8.1-13.6)
Larynx (C32) 9 3.3 2.8 (1.3-5.3)
Lung, bronchus and trachea (C33-34) 29 19.5 1.5 (1.0-2.1)
Melanoma (C43) 14 12.9 1.1 (0.6-1.8)
Breast (C50) 32 24.7 1.3 (0.9-1.8)
Vagina and vulva (C51-52, 57) 5 0.2 22.1 (7.1-51.5)
Penis (C60) 8 0.3 28.0 (12.1-55.2)
Prostate (C61) 8 16.2 0.5 (0.3-1.0)
Testis (C62) 19 7.9 2.4 (1.4-3.7)
Kidney (C64-66, C68) 9 8.9 1.0 (0.5-1.9)
Bladder (C67) 6 13.4 0.4 (0.2-1.0)
Brain and CNS (C70-72) 4 6 0.7 (0.2-1.7)
Thyroid (C73) 7 11.3 0.6 (0.2-1.3)
Hodgkin lymphoma (C81) 59 5 11.8 (9.0-15.2)
Myeloid leukaemia (C92) 4 2.7 1.5 (0.4-3.7)
^Cervix uteri was included in AIDS-defining-cancer after 1993. In bold are reported cancers with statistical significant SIRs (p < 0.05). We did not performed SIR for
cancers with less than 4 cases.
Abbreviations: ICD international classification of diseases, SIR standardized incidence ratio, 95% CI 95% confidence interval.
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analyses showed a higher risk of death for male gender,
year of enrolment before 1993, older age at enrolment,
intravenous drug use and the following variables included
as time-dependent covariates: low CD4 cell count, AIDS
event, cancer occurrence and the absence of antiretroviral
therapy (Table 4). However this model was not proper toTable 3 Age-standardized mortality rate according to
cancer-categories in period 1986–2012
Age-standardized mortality rate (95% CI)
Before 1998 After 1998
ADC 96.1 (57.5-113.5) 29.1 (23.0-35.3)
NADC 14.3 (0.0-35.3) 27.5 (22.5-32.6)
Without cancer 56.7 (45.4-68.0) 11.5 (10.5-12.6)
Patients with both ADC and NADC diagnosis (n = 36) were considered as ADC
or NADC on the basis of which cancer group first occurred.
Abbreviations: ADC AIDS-defining-cancer, NADC non-AIDS-defining-cancer,
95% CI 95% confidence interval.evaluate the cART effect, because of non-independence of
cART, CD4 cell count and AIDS event. Therefore, we esti-
mated the causal effect of cART using marginal structural
models: cART was strongly protective against mortality
with HR = 1.79 (1.49-2.16, p < 0.001) for sub-optimal-cART
(<3 drugs for at least 2 classes) and HR = 2.09 (1.83-2.39,
p < 0.001) for no therapy as respect to having received
optimal cART (data not shown in Table).
Discussion
This study describes AIDS-defining and non-AIDS-
defining cancer incidence and mortality for all causes in
a large multicenter Italian cohort of HIV/AIDS patients,
over a quarter century, up to 2012. As regards ADC, we
found that both incidence rates (IRs) and observed/ex-
pected incidence ratios (SIRs) decreased of about 2–3
fold, from before to after 1998. In contrast, for NADC
we observed a significant increase of the IRs but no
variation of SIRs from before to after 1998. As regards
Figure 1 a) Standardized mortality ratio (SMR) from 1986 to 2012); b) SMR stratified by gender-and age-class.
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from before to after 1998. The observed/ expected ratio
of death for all causes (SMR) declined after 1996 up to
2012, though it was still higher than that observed in the
general population, more in females than males, in 2012.
Inconsistent estimates of cancer incidence in HIV sub-
jects were reported in various studies in last decades.
These discrepancies can be attributed to the different
populations or subgroups investigated, such as HIV-
infected [2,4,5,8] or AIDS [10,13-16] patients or subjects
at high risk of exposure to oncogenic viruses (HCV/
HBV co-infected for liver cancer [9] or homosexual men
for HPV-related cancer [23]. However, most of these
findings were in agreement with ours, showing a decrease
in the incidence of ADCs and an increase of NADCs after
cART introduction [24,25]. Indeed cART determines im-
mune reconstitution and increases HIV-infected patients
life-expectancy [1], so as they are at risk of developing
age-related cancers as much as the general population.
However, the risk of developing some NADCs still
remains greater than in non-HIV-infected subjects espe-
cially virus-related cancer such as tongue and lingual
tonsil, rectum-Anus, liver, larynx, vagina and vulva, penis
cancer and Hodgkin lymphoma.
As regards overall mortality of the cohort, our findings
are in agreement with previous studies that reported a
substantial reduction in mortality rates among HIV-
infected subjects after 1998, mainly attributed to the
decline of deaths for AIDS-related conditions, thanks to
cART [1,3,18]. The global SMR in our study is slightly
higher than the values found in other HIV seropositive
cohorts in Italy and other countries [2,26-32], probably
because of the higher prevalence of IDUs in our cohort.In fact, overall mortality among IDUs is about 10 times
higher than the general population [33] and several HIV
seropositive IDUs still have a relatively poor prognosis,
due to drug use by itself, mental health illness, HCV/HBV
co-infection or poor adherence to cART [26,27,33-36].
The SMR decreased with age, from 20–24 to 50–54
years, with mortality rates close to the general population’s
ones in HIV-infected individuals of 70 years and older,
as previously described [2,7,12,18,29]. In fact, young
HIV-infected individuals have a higher risk of death than
the general population due to the presence of HIV-
infection itself, higher prevalence of intravenous drug use,
tobacco smoking or heavy alcohol consumption, HCV/
HBV co-infection or low compliance to therapy [33-36].
On the other hand, older HIV-positive individuals are
more strictly monitored than individuals of the same
age in the general population, getting earlier diagnosis
and treatment for possible co-morbidities [2]. We found
that women younger than 40 years had higher SMRs
than men, similarly to that reported in other cohorts
[2,7,12,35], maybe because they had less favorable
socio-economic or life-style factors or a delayed first
HIV test [2,18]. Further studies are necessary to find
out the causes of this gender difference.
In the multivariate analysis, we found that CD4 cell
count, AIDS event, cancer diagnosis occurrence, and the
underuse or the absence of cART were associated with
overall mortality. The protective effect of cART on risk of
death was also confirmed by the analysis with a marginal
structural model. These findings support the widespread
view that strict cART adherence and early diagnosis of
HIV infection are important for reducing the risk of death
among HIV-infected individuals [37].
Table 4 Univariate and multivariate Poisson regression with death for all-causes as the outcome
Univariate model Multivariate model
Variables Categories RR 95% CI RR* 95% CI
Gender Male vs Female 1.55 (1.42-1.70) 1.24 (1.12-1.36)
Age at enrolment (years) 18-34 Ref. Ref.
35-44 0.96 (0.88-1.06) 1.53 (1.36-1.71)
45-54 1.28 (1.12-1.47) 2.41 (2.05-2.83)
55-64 1.56 (1.27-1.92) 2.66 (2.13-3.33)
≥65 3.06 (2.24-4.19) 5.41 (3.89-7.52)
Year of enrolment 1986-1989 2.41 (1.99-2.91) 1.55 (1.25-1.94)
1990-1993 2.23 (1.84-2.70) 1.43 (1.15-1.78)
1994-1997 1.63 (1.34-1.98) 0.89 (0.71-1.10)
1998-2001 1.23 (1.00-1.51) 1.11 (0.90-1.36)
2002-2005 1.01 (0.81-1.27) 1.00 (0.80-1.26)
2006-2012 Ref. Ref.
IDUs Yes vs No 1.76 (1.62-1.90) 1.54 (1.40-1.70)
AIDS-event Yes vs No 17.55 (16.22-18.99) 3.75 (3.43-4.11)
HBV/HCV co-infection Yes vs No 0.95 (0.89-1.03)
CD4 cell count, cell/mm3 0-49 44.92 (37.90-53.25) 4.10 (3.62-4.65)
50-99 17.58 (14.48-21.33) 2.73 (2.36-3.16)
100-199 7.78 (6.45-9.39) 1.83 (1.62-2.08)
200-349 3.02 (2.45-3.67) 1.47 (1.31-1.65)
350-499 1.64 (1.32-2.04) 1.15 (1.01-1.30)
≥500 Ref. Ref.
Antiretroviral therapy cART Ref. Ref.
Subobtimal cART 3.26 (2.91-3.65) 2.18 (1.95-2.44)
No therapy 2.14 (1.96-2.33) 8.19 (7.23-9.27)
Cancer occurrence Without cancer Ref. Ref.
ADC 14.60 (12.51-17.03) 1.22 (1.08-1.38)
NADC 10.48 (8.49-12.93) 1.29 (1.12-1.50)
Time-dependent Poisson regression models, with observational period divided into intervals of 1-year duration. Gender, age at enrolment, year of enrolment,
intravenous drug use as risk factors and hepatitis C or B virus co-infection were included in the model as fixed covariates. CD4 cell count, AIDS events (ADC was not
considered as an AIDS event), antiretroviral therapy and cancer occurrence were included as time-dependent covariates, considering at enrolment and every year.
*Adjusted for all the variables in the model.
Abbreviations: RR relative risk, 95% CI 95% confidence interval, IDUs intravenous drug users, HBV/HCV co-infection hepatitis B virus/hepatitis C virus positivity,
cART combined antiretroviral therapy.
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MASTER cohort provides an unbiased “real world” sce-
nario of the clinical practice and epidemiological pattern
of HIV infection and AIDS disease throughout Italy,
from the beginning of HIV epidemic (1986) to today.
Second, this study has a long-term follow-up, longer
than most HIV cohort studies published so far, which
analyzed mortality only after 1998 [3-7,18].
This study has some limitations, too. First, as regards
cancer incidence, we did not perform a record-linkage
with Italian Cancer Registries, so some cancer cases
may have not been captured in this analysis, especially
NADCs. Therefore, the NADC incidence rates found in
our study may have underestimated the true values.However, we are confident that cancer records col-
lected by the HIV clinical personal were sufficiently
accurate to minimize possible loss of cases. Indeed,
in a previous study that we performed in Brescia using
a record linkage with a population base cancer re-
gistry, we found similar results showing a moderately
higher incidence of overall NADCs with SIR = 1.6
(1.4–1.9) [8].
As regards the vital status of subjects during and at
the end of the follow-up, we performed a record-linkage
of our data with those from mortality registries of Local
Health Authorities in some centers for about 30% of the
subjects and we found that the HIV original database
included 793 and the record linkage with Local Health
Raffetti et al. BMC Public Health  (2015) 15:235 Page 8 of 9Authorities allow us to add 23, corresponding to 3% of
the total deaths, thus producing a possible modest
underestimate of all-cause mortality. Therefore, we are
confident that the deaths recorded were also sufficiently
complete in the others centers.
Second, we used the cART data concerning drugs pre-
scriptions but did not consider patients’ adherence to ther-
apy. As a consequence, the positive prognostic value of
cART may be also higher than that we found in our study.
In conclusion, we found a dramatic reduction of inci-
dence rates of ADCs, which provides support for the
hypothesis of positive clinical effect of cART on the long
term, and no variation of NADC incidence with respect to
the general population over time. Overall mortality rates
decreased over time, though they are still higher than
those observed in the general population at present.
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